Pasithea Therapeutics Corp. Operating Income Loss

Quick Answer

Pasithea Therapeutics Corp. reported Operating Income Loss of -$20.86 million for the year ending 2025.

  • Pasithea Therapeutics Corp. showed a decrease of -46.4% in Operating Income Loss from 2024 to 2025.
  • This data is from Pasithea Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Pasithea Therapeutics Corp.'s Operating Income Loss has declined by 362.7%.
  • Historical annual values: Fiscal year 2025: -$20.86 million | Fiscal year 2024: -$14.25 million | Fiscal year 2023: -$15.98 million | Fiscal year 2022: -$12.59 million | Fiscal year 2021: -$4.51 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: